Acrivon Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 19, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 19, 2026

ACRV$1.57-0.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

	Common Stock
	Shares	Amount	AdditionalPaid-InCapital	AccumulatedOtherComprehensiveIncome (Loss)	AccumulatedDeficit	TotalStockholders’Equity
Balance at December 31, 2023	22,522,644	$23	$237,675	$(83)	$(116,420)	$121,195
Issuance of common stock in private placement, net of issuance costs of $3,360	8,235,000	8	66,629	—	—	66,637
Issuance of pre-funded warrants in private placement, net of issuance costs of $2,881	—	—	57,122	—	—	57,122
Exercise of common stock options	30,875	—	90	—	—	90
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for tax	442,745	—	(2,520)	—	—	(2,520)
Stock-based compensation expense	—	—	14,288	—	—	14,288
Unrealized gain on available-for-sale investments, net of tax	—	—	—	530	—	530
Net loss	—	—	—	—	(80,556)	(80,556)
Balance at December 31, 2024	31,231,264	$31	$373,284	$447	$(196,976)	$176,786
Exercise of common stock options	225	—	1	—	—	1
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for tax	417,367	—	(750)	—	—	(750)
Stock-based compensation expense	—	—	14,720	—	—	14,720
Unrealized loss on available-for-sale investments, net of tax	—	—	—	(336)	—	(336)
Net loss	—	—	—	—	(77,905)	(77,905)
Balance at December 31, 2025	31,648,856	$31	$387,255	$111	$(274,881)	$112,516

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.